NEW YORK, Nov. 1, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation into potential securities claims on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) arising from allegations that Y-mAbs may have issued materially misleading business information the investing public.

SO WHAT: If you have purchased Y-mAbs securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=9496 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.

WHAT IS THIS ABOUT: on October 31, 2022, market observation published an article titled, “Y-mAbs Therapeutics stock falls 42% after last week’s FDA Advisory Committee vote,” which said, “[s]Bunnies by Y-mAbs Therapeutics Inc. YMAB, [] fell 42.5% Monday in premarket trading after several banks downgraded the company’s shares and a Food and Drug Administration advisory committee voted against approving the company’s experimental treatment for neuroblastoma patients.”

The article goes on to say that the “committee voted 16-0 on Friday that there was insufficient evidence to say that omburtamab improves overall survival. JP Morgan downgraded the stock to underweight from neutral, with analysts saying, “We don’t think the recent news bodes well for investor confidence or for attribution of further pipeline value to trailing indicators, most of which are in their early stages of development.” .”

As a result of this news, Y-mAbs stock fell sharply during premarket and intraday trading on October 31, 2022.

WHY ROSES LAW: We encourage investors to seek qualified advisors with a track record in…